VectivBio Holding AG (VECT)
| Market Cap | 558.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -59.94M |
| Shares Out | 34.01M |
| EPS (ttm) | -1.76 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 16 |
| Last Price | $16.41 |
| Previous Close | $16.42 |
| Change ($) | -0.01 |
| Change (%) | -0.06% |
| Day's Open | 16.61 |
| Day's Range | 16.01 - 16.75 |
| Day's Volume | 31,893 |
| 52-Week Range | 12.62 - 37.70 |
Phase 2 trial will evaluate the efficacy of once-weekly apraglutide in increasing intestinal energy absorption in CIC patients with SBS-IF CIC patients represent over half of the total SBS-IF population...
Christian Meyer, currently Chief Development Officer, to assume the newly created position of Chief Operating Officer Senior leadership appointments strengthen VectivBio as it continues development of a...
BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- In a press release issued under the same headline earlier today by VectivBio Holding AG (Nasdaq: VECT), please note that in the first sentence of t...
BASEL, Switzerland, April 13, 2021 (GLOBE NEWSWIRE) -- VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical company focused on the discovery, development an...
Biotech stocks are making headlines on Friday as two companies join the public market via initial public offerings (IPOs) today. The post Biotech Stocks: 14 Things to Know as the VECT Stock IPO and RPHM...
VectivBio Holding AG, (“Vectiv” or “VectivBio”) (Nasdaq: VECT), a clinical stage biopharmaceutical...
VectivBio Holding, a Swiss Phase 3 biotech developing therapies for rare gastrointestinal disorders, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
VectivBio Holding AG has filed to go public with an IPO on the NASDAQ.
About VECT
VectivBio Holding is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Our goal is to become a leading, patient-centric, fully integrated global rare disease company. Our current product pipeline is focused on rare gastrointestinal, or GI, disorders, and we intend to in-license or acquire additional transformational, differentiated rare disease assets. Our product candidate, apraglutide, i... [Read more...]
| Industry Research and Development in Biotechnology | IPO Date Apr 9, 2021 |
| Stock Exchange NASDAQ | Ticker Symbol VECT |